Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful Retreatment of Chronic Hepatitis C Virus Genotype 1A Infection With Glecaprevir/Pibrentasvir in a Pediatric Patient With Developmental Disorder.

In vivo (Athens, Greece) - 1 Jan 2026

Ishikawa Toru, Fujii Koyata, Sakakibara Saeka, Odaira Aoi, Susa Mitsuru, Uchitsubo Takatoshi, Soichiro Okubo

Abstract excerpt

BACKGROUND/AIM: Although direct-acting antiviral (DAA) therapy is now available for pediatric patients with chronic hepatitis C virus (HCV) infection, the challenges associated with its use are similar to those observed in adults. In pediatric patients with chronic hepatitis C virus genotype 1A infection, the granular formulation of glecaprevir/pibrentasvir (GLE/PIB) can make oral administration difficult. CASE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Drug Combinations

Share to Lactams, Macrocyclic

Share to Pyrrolidines

Share to Quinoxalines

Share to Retreatment

Source

Open in PubMed Open full text

Identifiers

PMID: 41760324
DOI: 10.21873/invivo.14275
PMCID: PMC12949889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful Retreatment of Chronic Hepatitis C Virus Genotype 1A Infection With Glecaprevir/Pibrentasvir in a Pediatric Patient With Developmental Disorder.PMID 41760324Read ↗

Treatment of hepatitis C in children and adolescents: how far have we reached?Semantic proximity Read ↗

Management of Hepatitis C in Children - A New Paradigm.Semantic proximity Read ↗

Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.Semantic proximity Read ↗

Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older.Semantic proximity Read ↗

[Treatment of hepatitis C virus infection with new direct-acting antivirals agents in pediatrics. Case report].Semantic proximity Read ↗

Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children.Semantic proximity Read ↗

Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation.Semantic proximity Read ↗

Real-world efficacy and safety of glecaprevir/pibrentasvir in Japanese adolescents with chronic hepatitis C: a prospective multicenter study.Semantic proximity Read ↗

Treatment for chronic hepatitis C in children: a review.Semantic proximity Read ↗

Hepatitis C Virus in Children: Deferring Treatment in Expectation of Direct-Acting Antiviral Agents.Semantic proximity Read ↗

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.Semantic proximity Read ↗

Hepatitis C virus in infants and children.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.